NYSE:ABBV
AbbVie Inc.
A leading biopharmaceutical firm driving revenue growth via blockbuster immunology therapies and a robust pipeline of oncology and neuroscience candidates.
Key Metrics
Investment Thesis
Bull Case
AbbVie offers attractive dividend yield and capital return capabilities backed by strong operational cash flows exceeding $19B annually; the successful commercialization of SKYRIZI and RINVOLIQ provides a stable revenue floor while the oncology pipeline offers future upside potential.
Bear Case
Investors face substantial headwinds from impending patent expirations that could erode margins, leading to lower net profit compared to historical highs; the company's massive debt load and high interest expenses pose leverage risks during periods of rising rates or slower growth.
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company specializing in treating serious diseases such as immunology, oncology, and neuroscience. Operating primarily in the United States and international markets, the company delivers key products like Skyrizi, Rinvoq, and Imuvu through its innovative drug portfolio.
Analysis
Management Discussion
The company reported robust operational cash flow of $19.03B, which helped fund significant share returns including $11.66B in dividends and $980M in repurchases despite a net profit decline to $4.23B. While total revenue reached $61.16B in 2025, the company navigates the transition from Humira's expiration by leveraging growth in its immunology franchises.
Industry Overview
The global biopharmaceutical industry is characterized by intense R&D competition and rapid technological advancements in biologics and cell therapies; companies must continuously innovate to offset patent losses and maintain market share against generic alternatives.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $58.05B | $54.32B | $56.33B | $61.16B |
| Cost of Revenue | $17.41B | $20.41B | $16.90B | $18.20B |
| Gross Profit | $40.64B | $33.90B | $39.43B | $42.96B |
| Operating Expenses | $22.52B | $21.15B | $30.29B | $27.88B |
| Operating Income | $18.12B | $12.76B | $9.14B | $15.07B |
| G&A | $15.26B | $12.87B | $14.75B | $14.01B |
| Stock-Based Comp | $671.0M | $747.0M | $911.0M | $955.0M |
| Depreciation | $778.0M | $752.0M | $764.0M | $762.0M |
| Amortization | $7.69B | $7.95B | $7.62B | $7.38B |
| Other OpEx | $7.26B | $8.27B | $15.54B | $13.87B |
| Non-Operating Income | $-4.64B | $-6.51B | $-5.42B | $-8.48B |
| Interest Expense | $2.23B | $2.22B | $2.81B | $2.89B |
| Pre-Tax Income | $13.48B | $6.25B | $3.72B | $6.60B |
| Income Tax | $1.63B | $1.38B | $-570.0M | $2.36B |
| Continuing Ops | $11.85B | $4.87B | $4.29B | $4.23B |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $11.85B | $4.87B | $4.29B | $4.23B |
| Minority Interest | $9.0M | $10.0M | $8.0M | $7.0M |
| Net to Common | $11.84B | $4.86B | $4.28B | $4.23B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $28.46B | $33.00B | $25.58B | $29.06B |
| Cash & Equivalents | $9.20B | $12.81B | $5.52B | $5.23B |
| Marketable Securities | $28.0M | $2.0M | $31.0M | $28.0M |
| Accounts Receivable | $11.25B | $11.15B | $10.92B | $12.59B |
| Inventory | $3.58B | $4.10B | $4.18B | $4.95B |
| Other Current Assets | $4.40B | $4.93B | $4.93B | $6.26B |
| Long-Term Assets | $110.34B | $101.71B | $109.58B | $104.90B |
| PP&E (Net) | $4.93B | $4.99B | $5.13B | $5.63B |
| Intangibles | $67.44B | $55.61B | $60.07B | $52.64B |
| Goodwill | $32.16B | $32.29B | $34.96B | $35.64B |
| Operating Leases | $737.0M | $744.0M | $723.0M | $737.0M |
| LT Investments | $241.0M | $304.0M | $279.0M | $268.0M |
| Other LT Assets | $4.83B | $7.77B | $8.42B | $9.98B |
| Total Assets | $138.81B | $134.71B | $135.16B | $133.96B |
| Current Liabilities | $29.54B | $37.84B | $38.75B | $43.29B |
| Accounts Payable | $2.93B | $3.69B | $2.94B | $3.59B |
| Current Leases | $166.0M | $166.0M | $178.0M | $194.0M |
| Other Current Liab | $23.76B | $31.20B | $32.69B | $36.40B |
| Long-Term Liabilities | $91.98B | $86.47B | $93.05B | $93.90B |
| LT Operating Leases | $754.0M | $735.0M | $697.0M | $689.0M |
| Other LT Liab | $88.24B | $83.56B | $91.09B | $92.85B |
| Total Liabilities | $121.52B | $124.31B | $131.80B | $137.19B |
| Shareholders' Equity | $17.29B | $10.40B | $3.36B | $-3.23B |
| Retained Earnings | $4.78B | $-1.00B | $-7.90B | $-15.49B |
| AOCI | $-2.20B | $-2.31B | $-1.93B | $-1.14B |
| Treasury Stock | $4.59B | $6.53B | $8.20B | $9.15B |
| Total L&E | $138.81B | $134.71B | $135.16B | $133.96B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $11.85B | $4.87B | $4.29B | $4.23B |
| Non-Cash Adjustments | $8.55B | $14.07B | $17.80B | $12.06B |
| Working Capital Changes | $4.55B | $3.89B | $-3.28B | $2.74B |
| Cash from Operations | $24.94B | $22.84B | $18.81B | $19.03B |
| Capital Expenditures | $695.0M | $777.0M | $974.0M | $1.21B |
| Cash from Investing | $-623.0M | $-2.01B | $-20.82B | $-6.64B |
| Debt Issuances | $2.00B | — | $16.96B | $3.99B |
| Share Buybacks | $1.49B | $1.97B | $1.71B | $980.0M |
| Dividends Paid | $10.04B | $10.54B | $11.03B | $11.66B |
| Cash from Financing | $-24.80B | $-17.22B | $-5.21B | $-12.72B |
| FX Effect | $-62.0M | $5.0M | $-65.0M | $42.0M |
| Net Change in Cash | $-545.0M | $3.61B | $-7.29B | $-295.0M |
| Beginning Cash | $9.75B | $9.20B | $12.81B | $5.52B |
| Ending Cash | $9.20B | $12.81B | $5.52B | $5.23B |
Frequently Asked Questions
How does AbbVie Inc. make money?
The company generates revenue primarily through its Immunology segment featuring high-growth SKYRIZI and RINVOLIQ, the Oncology portfolio including Imnovid and Vencloxcel, and the Neuroscience segment with Imuvu and other targeted therapies.
What are the main risks for ABBV?
Patent cliffs on legacy products like Humira creating significant revenue pressure; potential regulatory delays or pricing negotiations impacting future growth rates; reliance on a concentrated portfolio of blockbuster drugs amidst high R&D costs.
What is ABBV's competitive advantage?
AbbVie possesses a deep pipeline of proprietary biologics addressing unmet needs in immunology, oncology, and neuroscience; its strong commercial infrastructure ensures effective global market penetration for new launches.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.